A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.
Farlow
M
M
Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202-5111, USA. mfarlow@iupui.edu
Anand
R
R
Messina
J
J
Hartman
R
R
Veach
J
J
D000367:Age Factors; D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002219:Carbamates / Q000008:administration & dosage* / Q000009:adverse effects; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D003071:Cognition / Q000187:drug effects / Q000502:physiology; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D048448:Phenylcarbamates; D000068836:Rivastigmine; D013997:Time Factors; D016896:Treatment Outcome
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine